The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Market Size Is Forecasted For The Synagis Market By 2030 Based On Its 2026 Value?
The historical growth stemmed from a rise in RSV infections among infants, accompanied by an expanding understanding of preventive monoclonal therapies. Further contributions came from the enlargement of neonatal intensive care units, the availability of reimbursement for RSV prevention, and the acquisition of regulatory approvals for pediatric biologics.
During the projected timeframe, an uplift in growth is expected, stemming from increased capital allocation towards advanced RSV prevention treatments, a heightened emphasis on extended-duration monoclonal antibodies, the enlargement of biologic production capabilities, a rise in spending on pediatric healthcare, and a wider embrace of precise immunotherapy strategies.
Key developments anticipated in the forecast period involve a growing acceptance of monoclonal antibody-based RSV prophylaxis, an intensifying focus on pediatric immunotherapies for prevention, the broadening of distribution networks for biologics requiring cold-chain management, an increasing priority placed on protecting high-risk infants, and enhanced scalability in the manufacturing of biologics.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20304&type=smp
What Are The Main Drivers Accelerating The Growth Of The Synagis Market?
The increasing occurrence of chronic respiratory conditions is anticipated to stimulate the growth of the synagis market. Chronic respiratory conditions are prolonged ailments that affect the lungs and airways, leading to continuous breathing issues. The prevalence of these conditions can be attributed to several factors, including an aging population, lifestyle choices and smoking, genetic and occupational influences, and environmental pollution. Synagis (palivizumab) works to prevent severe respiratory syncytial virus (RSV) infections in at-risk infants and children, thereby reducing complications and exacerbations in those with chronic respiratory conditions. For instance, in June 2025, the World Health Organization (WHO), a specialized agency of the United Nations based in Switzerland, reported that chronic respiratory diseases impact more than 80 million individuals, with many more undiagnosed, according to a new WHO and European Respiratory Society report. Thus, the rising prevalence of chronic respiratory conditions is driving the expansion of the synagis market.
How Is The Synagis Market Structured Across Different Market Segments?
The synagis market covered in this report is segmented –
1) By Clinical Indication: Respiratory Syncytial Virus (RSV) Prophylaxis, Premature Infants With Bronchopulmonary Dysplasia (BPD), Congenital Heart Disease (CHD), Immunocompromised Infants And Children
2) By Formulation: 50 Milligrams (mg)/0.5 Milliliters (mL), 100 Milligrams (mg)/1 Milliliters (mL)
3) By Distribution Channel: Wholesale Distributors, Online Retailers
4) By End-User: Pediatric, Adults
What Trends Are Impacting The Synagis Market?
Within the Synagis market, leading companies are prioritizing securing drug approvals to offer preventive treatment for respiratory syncytial virus (RSV), thereby addressing a considerable gap in medical care. This approval process involves regulatory bodies assessing a drug’s safety, effectiveness, and quality, drawing on clinical trial findings prior to its authorization for patient use. An illustration of this trend is AstraZeneca Pharma India Ltd., an India-based biopharmaceutical firm, which in September 2023, received authorization from the Central Drugs Standard Control Organisation (CDSCO) to commercialize palivizumab, a preventive treatment for RSV. This injectable medication, palivizumab, is supplied as 100 mg/ml in individual-dose vials of 50 mg/0.5 ml and 100 mg/ml, intended for intramuscular administration. Its indications include infants delivered at =35 weeks gestation, children needing therapy for bronchopulmonary dysplasia (BPD), and individuals with hemodynamically significant congenital heart disease (CHD). Significantly, this marks the introduction of the first preventive therapy for RSV in India.
Which Industry Players Are Present In The Synagis Market?
Major companies operating in the synagis market are Swedish Orphan Biovitrum AB
Access The Complete Synagis Market Report:
https://www.thebusinessresearchcompany.com/report/synagis-global-market-report
Which Region Contributes The Most To The Synagis Market?
North America was the largest region in the synagis market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the synagis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model